European Medicines Agency approves cefiderocol for treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options

Approval based on data from APEKS-cUTI, APEKS-NP and CREDIBLE-CR studies; cefiderocol demonstrated efficacy in patients with complicated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis and patients with bacteraemia.

SPS commentary:

Cefiderocol, the first siderophore cephalosporin, is the first to provide coverage against all Gram-negative pathogens considered of critical priority by the World Health Organisation – carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae.